Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS)
- 23 August 2017
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 96 (11) , 1825-1832
Abstract
The hypomethylating agents azacytidine and decitabine are unaffordable for many patients with MDS. The combination of the DNA methyltransferase inhibitor hydralazine and the histone deacetylase inhibitor valproate has shown preliminary efficacy in MDS. The aim of this study is to evaluate the clinical efficacy and safety of hydralazine/valproate in a case series of MDS patients treated in a compassionate manner. Hydralazine was dosed according to the acetylation genotype of patients (slow acetylators 83 mg daily; fast acetylators 182 mg daily), and valproate was dosed at 30 mg/kg/day. Both drugs were given daily until disease progression. Response and toxicity were evaluated with the International Working Group criteria and CTCAE, version 4, respectively. Survival parameters were estimated with the Kaplan-Meier method. From 2009 to 2012, 14 patients were treated. The median age ± SD was 55.2 ± 19.52 (range 23–87) years. According to the IPSS, cases were graded as intermediate-1 (n = 8/14; 57.2%) or intermediate-2 (n = 6/14; 42.8%). Responses were as follows: five (35.7%) complete response, one (7.1%) partial response, and two (14.28%) became transfusion independent. The mean duration of response ± SD was 60 ± 35.28 months (range 5–94). Three patients progressed to AML. At a median follow-up of 57 months (range 1–106), the median OS was 27 months. At that point, five patients remained on the treatment, one with partial response and four with complete response. The median OS was not reached in the eight patients who saw a clinical benefit from the treatment, in comparison to an OS of 7 months in the six patients who had no treatment. The combination of hydralazine and valproate is safe and effective in MDS, and its further testing is highly desirable.Keywords
This publication has 35 references indexed in Scilit:
- Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II studyExpert Opinion on Investigational Drugs, 2017
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Myelodysplastic syndromes: 2015 Update on diagnosis, risk‐stratification and managementAmerican Journal of Hematology, 2015
- Hydralazine–valproate: a repositioned drug combination for the epigenetic therapy of cancerExpert Opinion on Drug Metabolism & Toxicology, 2014
- A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid CancersTranslational Oncology, 2014
- Hypomethylating Agents and Other Novel Strategies in Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trialAnnals of Hematology, 2010
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002